Shares subscribed by board and management in Cline's ongoing rights issue

Series A shares are subscribed to in the ongoing rights issue, which runs until July 12.

Acting CEO Hanne Evenbratt and board member Patrik Sundh subscribe for Series A shares in Cline's ongoing rights issue. Hanne subscribes to 312,500 Series A shares and Patrik 650,000 Series A shares, for a total of SEK 231,000.

These subscriptions of shares are in addition to the previously announced board members' subscription of Series B shares, details can be found in Cline’s memorandum. Through these subscriptions, the board and management show their continued trust and foundational faith in Cline's future prospects.

The last day for subscription is July 12, 2023.

For more information, please contact:

Hanne Evenbratt, Interim CEO

Email: hanne.evenbratt@clinescientific.com

Phone: +46 704 88 79 23

Cline Scientific AB (publ)                                                
Pepparedsleden 1
AstraZeneca BioVentureHub                                               Email: info@clinescientific.com
431 53  MÖLNDAL                                                             Website: www.clinescientific.com

About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.